The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion Following Oral Administration in Healthy Male Subjects (an Open-label, One-sequence Trial)
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
At a glance
- Drugs BI 187004 CL (Primary) ; Bupropion; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 04 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.